RUA Life Sciences has published a trading update for the 12 months to March 2025, demonstrating strong progress on its strategy to deliver near-term profitability by focusing on its revenue-generating divisions. Group revenue is expected to be £4.1m, including £1.3m from the Abiss acquisition. Biomaterials revenue of £0.6m was in line with our forecast, while the underlying Medical Devices & Components (MD&C) division generated revenues of £2.2m, up 32% YoY and ahead of our forecast £1.9m. Cash ....
